Immuno Cure secures HK$8 M funding support for HIV vaccine clinical trial
Immuno Cure BioTech, a clinical stage biotechnology group based in the Hong Kong Science Park specialising in DNA vaccines and immunotherapies, has announced that Hong Kong Science and Technology Parks Corporation (HKSTP) has awarded maximum amount of HK$8 million matching funding to Immuno Cure under the Clinical Translational Catalyst programme (CTC Programme) for conducting the Phase 1 Clinical Trial of ICVAX, a therapeutic vaccine against HIV/AIDS.
The CTC Programme funding of HK$8 million will be drawn down by Immuno Cure in the next 27 months in various tranches according to the progress of the clinical trial of ICVAX.
Immuno Cure previously received the University-Industry Collaboration Programme and Cash Rebate Scheme funding of some HK$8.4 million from the Government
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!